Tainan

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Lung cancer3 trials
• Multiple sclerosis3 trials
• Stroke3 trials
• Colorectal cancer2 trials
• Familial hypercholesterolaemia2 trials
• Metastatic breast cancer2 trials
• Prostate cancer2 trials
• Childhood cancers1 trial
• Epilepsy1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• and 7 more

Phase

• Phase 317 trials
• Phase 25 trials
• Phase 12 trials
• Phase 1/21 trial

Status

• Active, not recruiting13 trials
• Completed6 trials
• Recruiting3 trials
• Terminated3 trials

Lead sponsor

• Novartis Pharmaceuticals25 trials

Running trials

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

  NCT06726148· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

  NCT06744920· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

  NCT04940052· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

  NCT04926818· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

  NCT03333343· Phase 1· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

  NCT02962414· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Ribociclib (LEE011) Rollover Study for Continued Access

  NCT02934568· Phase 2· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

  NCT04952753· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

  NCT04864392· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

  NCT03867201· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

  NCT03798626· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

  NCT03785405· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

  NCT00680901· Phase 3· Novartis Pharmaceuticals· Source